Entrada Therapeutics, Inc. (TRDA): R&D Expense
$142.27M
Year ended 2025-12-31
$140.74M
Trailing 12 months to 2026-06-30
+28.8%
3-year compound annual growth
+46.5%
5-year compound annual growth
| Period ended | R&D Expense | Change YoY | Source filing |
|---|---|---|---|
| 2025-12-31 | $142.27M | +13.5% | 2026-02-26, From 2025-01-01 |
| 2024-12-31 | $125.31M | +25.5% | 2026-02-26, From 2024-01-01 |
| 2023-12-31 | $99.88M | +50.0% | 2025-02-27, From 2023-01-01 |
| 2022-12-31 | $66.61M | +85.4% | 2024-03-13, From 2022-01-01 |
| 2021-12-31 | $35.93M | +70.2% | 2023-03-06, From 2021-01-01 |
| 2020-12-31 | $21.10M | n/a | 2022-03-15, From 2020-01-01 |
R&D Expense at similar companies
| Company | Year ended | R&D Expense | Change YoY |
|---|---|---|---|
| Entrada Therapeutics, Inc. (TRDA) | 2025-12-31 | $142.27M | +13.5% |
| Celularity Inc (CELU) | 2025-12-31 | $15.03M | -13.6% |
| Alumis Inc. (ALMS) | 2025-12-31 | $386.00M | +45.4% |
| Cue Biopharma, Inc. (CUE) | 2025-12-31 | $37.74M | +4.0% |
| NewAmsterdam Pharma Co N.V. (NAMS) | 2025-12-31 | $141.83M | -6.3% |
| Foghorn Therapeutics Inc. (FHTX) | 2025-12-31 | $85.47M | -9.6% |
| Verastem, Inc. (VSTM) | 2025-12-31 | $114.60M | +40.9% |
| CASI Pharmaceuticals, Inc. (CASIF) | 2025-12-31 | $6.31M | -29.3% |
| Scynexis Inc (SCYX) | 2025-12-31 | $22.28M | -15.6% |
Compare TRDA, CELU, ALMS, CUE side by side · Screen every company in Pharmaceutical Preparations ↗